The QualityStocks Daily Tuesday, May 31st, 2022

Today's Top 3 Investment Newsletters

QualityStocks(TXMD) $9.9300 +364.02%

Green Car Stocks(MULN) $1.4000 +44.90%

Tiny Gems(LQWDF) $0.1428 +27.61%

The QualityStocks Daily Stock List

Seres Therapeutics (MCRB)

MarketClub Analysis, InvestorPlace, MarketBeat, Kiplinger Today, The Street, StreetInsider, Schaeffer's, TradersPro, BUYINS.NET, Daily Trade Alert,, QualityStocks, Wealth Insider Alert, StockMarketWatch, TraderPower, AllPennyStocks, Stock Market Watch, The Online Investor, Top Pros' Top Picks, Investment U, Trades Of The Day and Rick Saddler reported earlier on Seres Therapeutics (MCRB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Seres Therapeutics Inc. (NASDAQ: MCRB) (FRA: 1S9) is a microbiome therapeutics platform firm that is focused on the development of bacterial consortia that can functionally interact with host tissues and cells to treat illnesses.

The firm has its headquarters in Cambridge, Massachusetts and was incorporated in 2010, on October 18th by Noubar B. Afeyan, David A. Berry and Geoffrey von Maltzahn. Prior to its name change in May 2015, the firm was known as Seres Health Inc. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the globe.

The company is party to license and collaboration agreements with Memorial Sloan Kettering Cancer Center and Nestec Ltd. It develops biological drugs which help restore patient health by repairing the dysbiotic microbiome’s function.

The enterprise’s product candidates include a cultivated bacteria microbiome drug dubbed SER-155, which is undergoing phase 1b clinical trials testing its effectiveness in reducing incidences of bloodstream infections, gastrointestinal infections and graft vs. host diseases in immuno-compromised patients receiving solid organ transplants and allogeneic hematopoietic stem cell transplants. It also develops an oral microbiome known as SER-109, which has concluded phase 3 clinical trials evaluating its efficacy in treating clostridium difficile infections.

The firm is focused on advancing its SER-109 candidate, which has shown promise in preventing the recurrence of clostridium difficile infections. The success and approval of this candidate in the treatment of this infection will greatly benefit patients who suffer this indication and help create shareholder value for its stakeholders.

Seres Therapeutics (MCRB), closed Tuesday's trading session at $3.1, off by 2.8213%, on 1,040,031 volume. The average volume for the last 3 months is 1.04M and the stock's 52-week low/high is $2.905/$25.055.

Edgewise Therapeutics (EWTX)

MarketBeat reported earlier on Edgewise Therapeutics (EWTX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Edgewise Therapeutics Inc. (NASDAQ: EWTX) is a biopharmaceutical firm that is engaged in the development of small molecule therapies for musculoskeletal illnesses.

The firm has its headquarters in Boulder, Colorado and was incorporated in 2017. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves patients in the United States, with a focus on those in the state of Colorado.

The company is primarily focused on discovering, developing and commercializing rare muscle disorder treatments. Its objective is to find new approaches to treat these ailments and improve the lives of patients living with the disorders. The company’s platform uses custom-built translatable and throughput systems which can measure integrated muscle function in organ extracts to find small molecule precision medicines which can regulate certain proteins in muscle tissue.

The enterprise develops precision product candidates under its product pipeline, which is comprised of an orally administered selective, allosteric, type II myosin small molecule inhibitor dubbed EDG-5506, which has been designed to address the main cause of dystrophinopathies like Beckermuscular dystrophy and Duchenne muscular dystrophy. This inhibitor has completed phase 1 clinical trials evaluating its effectiveness. The enterprise also has a number of research programs, which include EDG-003, EDG-002 and EDG-6289.

The company is currently focused on advancing its EDG-002 program, which is focused on identifying cardiac muscle modulators which target inherited hypertrophic cardiomyopathy. It hopes that the program will become the new standard of care for the treatment of this cardiomyopathy, which will not only benefit patients but also encourage more investments into the company.

Edgewise Therapeutics (EWTX), closed Tuesday's trading session at $6.25, up 2.9654%, on 196,192 volume. The average volume for the last 3 months is 191,901 and the stock's 52-week low/high is $5.405/$29.0699.

Heron Therapeutics (HRTX)

InvestorPlace, Market Report, MarketBeat, MarketClub Analysis, Kiplinger Today, Schaeffer's, BUYINS.NET, StreetInsider, Barchart, StockMarketWatch, TraderPower, The Street, Top Pros' Top Picks, TopStockAnalysts, Hit and Run Candle Sticks,, Wealth Insider Alert, Dividend Opportunities, Cabot Wealth, Investopedia,,, Rick Saddler, Zacks, StreetAuthority Daily, Trades Of The Day, VectorVest, Weekly Wizards and RedChip reported earlier on Heron Therapeutics (HRTX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Heron Therapeutics Inc. (NASDAQ: HRTX) (LON: 0J4V) (FRA: AXD2) is a biotechnology firm that is focused on the development of therapies that address unmet patient needs.

The firm has its headquarters in San Diego, California and was incorporated in February 1983. Prior to its name change in January 2014, the firm was known as A.P. Pharma Inc. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers in the United States.

The enterprise’s product candidates use a drug delivery technology dubbed Biochromoner, which has been designed to deliver therapeutic levels of short-acting pharmacological agents over a specified period with one administration. Its candidates include a dual-acting local anesthetic dubbed Zynrelef, which delivers a combined dose of meloxicam, which is a non-steroidal anti-inflammatory drug and bupivacaine, which is a local anesthetic; and an investigational agent known as HTX-019, which has been designed to prevent post-op nausea and vomiting. It also develops an IV aprepitant formulation dubbed Cinvanti, which has been designed to prevent delayed and acute nausea and vomiting linked to moderately and highly emetogenic cancer chemotherapy; and an extended-release injection known as Sustol, to prevent delayed and acute nausea and vomiting linked to anthracycline and cyclophosphamide combination chemotherapy treatments.

The company is focused on boosting the sale of the products under its oncology care franchise following Zynrelef’s approval by the FDA for use in a number of indications. This will not only help benefit more patients with these fatal illnesses but also bring in more revenues into the company.

Heron Therapeutics (HRTX), closed Tuesday's trading session at $3.3, off by 1.7857%, on 2,126,909 volume. The average volume for the last 3 months is 2.127M and the stock's 52-week low/high is $3.05/$16.63.

Infinera Corp (INFN)

StocksEarning, MarketClub Analysis, MarketBeat, Hit and Run Candle Sticks,, Daily Trade Alert, Zacks, The Street, StreetInsider, InvestorPlace, All about trends, Trades Of The Day, SmarTrend Newsletters, Market Report, Schaeffer's, Kiplinger Today, The Online Investor, BUYINS.NET, StockMarketWatch, TradingMarkets, MarketDNA, Barchart, StreetAuthority Daily, QualityStocks, TradersPro, Weekly Wizards, Wealth Insider Alert, BullRally, CrashTrade, TopPennyStockMovers, Greenbackers, Top Pros' Top Picks, Schaeffer’s, Investor Update, Agora Financial, InvestorsUnderground, StockEarnings, Stock Traders Chat,, Short Term Wealth, One Hot Stock, Penny Detectives and The Motley Fool reported earlier on Infinera Corp (INFN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Infinera Corp. (NASDAQ: INFN) (FRA: IX6) is engaged in the provision of optical transport networking software, equipment and services.

The firm has its headquarters in San Jose, California and was incorporated in December 2000 by Jagdeep Singh, Drew Daniel Perkins and David F. Welch. Prior to its name change, the firm was known as Zepton Networks. It operates as part of the communications equipment industry, under the technology sector. The firm serves consumers around the globe.

The enterprise’s product portfolio is comprised of its 7100 and 7090 series for transport platforms; its FlexILS open optical line system which can also connect to 3rd party terminal equipment platforms; its Groove series for sled and modular-based platforms to support a range of transport network applications; and its 7300 series, which is a coherent optical transport system that is SDN-ready. It also offers the XT series, which is a platform that’s designed to power cloud-scale network services over subsea, long-haul, DCI and metro networks; the mTera series, which is a network transport solution; the XTC series, which integrates optical WDM transmission and digital OTN switching; and the XTM series which enables metro connectivity solutions. The enterprise serves telecommunication service providers, cable providers, ISPs, wholesale carriers, large enterprises, research and education institutions and government entities, among others.

The company, which recently announced its latest financial results, is focused on expanding its addressable markets and margins. This will not only bring in additional revenues and encourage more investments into the company but also bolster its growth.

Infinera Corp (INFN), closed Tuesday's trading session at $5.73, off by 1.8836%, on 2,105,012 volume. The average volume for the last 3 months is 2.105M and the stock's 52-week low/high is $5.24/$10.89.

Jounce Therapeutics (JNCE)

MarketBeat, StockMarketWatch, MarketClub Analysis, Trades Of The Day, TradersPro, StreetInsider, Schaeffer's, Zacks, QualityStocks,, InvestorPlace, Daily Trade Alert and BUYINS.NET reported earlier on Jounce Therapeutics (JNCE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Jounce Therapeutics Inc. (NASDAQ: JNCE) (FRA: 21J) is a clinical-stage immunotherapy firm that is focused on the development of therapies to treat cancer.

The firm has its headquarters in Cambridge, Massachusetts and was incorporated in 2013 by Padmanee Sharma, Robert Schreiber, James P. Allison, Thomas F. Gajewski, Drew M. Pardoll and Louis M. Weiner. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers in the United States.

The company develops therapies which strengthen the immune system to attack tumors and offer long-lasting benefits to patients. It has developed a suite of integrated technologies which consist of its Translational Science platform that allows it to interrogate tumor molecular and cellular composition.

The enterprise’s product pipeline is comprised of an anti-CCR8 monoclonal antibody dubbed JTX-1811, which has been designed to deplete intra-tumoral T regulatory cells in the microenvironment of tumors; and a formulation dubbed JTX-1484, for myeloid. It also develops an antibody dubbed JTX-8064, which has been designed to bind to leukocyte immunoglobulin-like receptor B2. Receptor B2 is a cell surface receptor that expresses itself on macrophages. In addition to this, the enterprise develops a monoclonal antibody dubbed vopratelimab, which is undergoing phase 2 clinical trials and has been designed to activate and bind itself to the Inducible T cell Co-stimulator, which is a protein found on T cell surfaces in a range of solid tumors.

The firm is focused on building its pipeline of diverse immunotherapy candidates, which will offer long-lasting and meaningful benefit to cancer patients when approved.

Jounce Therapeutics (JNCE), closed Tuesday's trading session at $3.87, off by 4.914%, on 160,940 volume. The average volume for the last 3 months is 160,940 and the stock's 52-week low/high is $3.73/$9.81.

TherapeuticsMD (TXMD)

MarketClub Analysis, MarketBeat, InvestorPlace, The Street, BUYINS.NET, StockMarketWatch, StreetInsider, Schaeffer's, Market Report, Barchart,, Wall Street Resources, StockOodles, TraderPower, Kiplinger Today, ProTrading Research, Wealth Insider Alert, QualityStocks, TradersPro, StreetAuthority Daily, CRWEFinance, CRWEWallStreet, BestOtc, CRWEPicks, Hit and Run Candle Sticks, INO Market Report, DrStockPick, Investing Futures, InvestorsUnderground, PennyToBuck, StockHotTips, Street Insider, TopPennyStockMovers, Trades Of The Day, Trading Concepts and PennyOmega reported earlier on TherapeuticsMD (TXMD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

TherapeuticsMD Inc. (NASDAQ: TXMD) (FRA: 29T) is a pharmaceutical firm that is engaged in the development and commercialization of over-the-counter products as well as generic and branded prescriptions for women.

TherapeuticsMD Inc. has its headquarters in Boca Raton, Florida and was founded by Brian A. Bernick and Robert G. Finizio in 2008. The firm sells its prescription prenatal hormone therapy and vitamin drug products to retail pharmacy and wholesale distributors. TherapeuticsMD Inc. operates in the United States.

TherapeuticsMD uses its technology, dubbed SYMBODA, to develop advanced hormone therapy pharmaceuticals that have been designed to reduce the symptoms of and alleviate the health risks that arise from hormone deficiencies related to menopause.

TherapeuticsMD Inc. has developed a ring-shaped contraceptive vaginal system known as ANNOVERA, which is a bio-identical hormone therapy developed to help treat moderate-to-severe vasomotor symptoms dubbed BIJUVA and IMVEXXY, which has been indicated for treating moderate-to-severe dyspareunia. The firm’s preclinical projects include transdermal patch product candidates dubbed TX-0008HR and TX-00THR; a progesterone and estradiol transdermal cream known as TX-006HR; a progesterone transdermal cream called TX-005HR and an oral estradiol and progesterone formulation christened TX-009HR. TherapeuticsMD Inc. also manufactures and distributes generic and branded prescription prenatal vitamins under the BocaGreenMD, vitaMedMD, vitaPearl and vitaTrue brands.

TherapeuticsMD Inc.’s IMVEXXY product was recently approved by Health Canada as a treatment for postmenopausal dyspareunia, which has been indicated for postmenopausal women who experience pain before, during or after sex. Around 75% of women have painful intercourse at some time and the product, which is marketed in Canada as well as the U.S. helps alleviate these symptoms as well as the resultant pain.

TherapeuticsMD (TXMD), closed Tuesday's trading session at $9.93, up 364.0187%, on 7,452,960 volume. The average volume for the last 3 months is 7.453M and the stock's 52-week low/high is $1.99/$69.50.

Aesther Healthcare Acquisition Corp. (AEHA)

We reported earlier on Aesther Healthcare Acquisition Corp. (AEHA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Aesther (NASDAQ: AEHA) is a special purpose acquisition company (“SPAC”) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company recently announced its entry into an agreement and plan of merger (the “merger agreement”) with United Gear & Assembly Inc., a manufacturer of high precision gears for electric vehicles and other rapidly developing industries. Upon closing of the transaction, United Gear will be a wholly-owned subsidiary of Aesther, and Aesther will change its name to EVGT LTD, with its common stock and warrants expected to be listed on the Nasdaq, under the symbols EVGT and EVGTW, respectively. “We believe the combination of Aesther and United Gear will result in a profitable public company that provides a positive valuation with increasing revenue into a market category that has already demonstrated significant success with room for continued growth,” said Suren Ajjarapu, chairman and CEO of Aesther. “United Gear’s long-standing customer relationships, supply chain expertise, history of quality and precision, and U.S. headquarters and manufacturing facilities make it an attractive partner for our investors, and we look forward to collaborating to complete its entry into the public market. United Gear is a strategic U.S. asset that is capitalizing on the trends towards U.S. manufacturing reshoring.”

To view the full press release, visit

About Aesther Healthcare Acquisition Corp.

Aesther is a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Its principals possess public and private market investing experience and operational knowledge to bring value added benefits to the target, including strong access to transformative technologies. The current management team, which has a diverse background, believes it can source, evaluate and transact with potential future acquisition targets, as well as the ability to step into management roles and/or operational support, if needed. The Aesther team has substantial experience investing in and operating businesses in multiple sectors, as well as a significant long-term track record in creatively structuring transactions to unlock and maximize value.

Aesther Healthcare Acquisition Corp. (AEHA), closed Tuesday's trading session at $10.1, off by 0.098912%, on 1,560 volume. The average volume for the last 3 months is 1,560 and the stock's 52-week low/high is $9.95/$10.12.

BIT Mining Ltd. (BTCM)

MarketClub Analysis, QualityStocks, Schaeffer's and StocksEarning reported earlier on BIT Mining Ltd. (BTCM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

BNP Paribas, a French bank, has joined a platform owned by J.P. Morgan in a bid to start leveraging digital tokens while undertaking short-term trading activities in the markets of fixed-term financial assets. This comes at a time when major banks are ramping up efforts to modernize the sector by adopting blockchain technology.

The blockchain platform, dubbed Onyx Digital Assets, has so far seen deals worth $300 billion completed since December 2020 when the platform was launched. This platform facilitates repo (or repurchase) deals in which investors are allowed to borrow high-quality financial assets for a day or so. Repo markets also make it possible for central banks around the world to conduct their mandate of implementing monetary policies.

According to official records, almost eight in 10 of all repo deals involves government bonds. This makes the repo market a highly sought-after source of top-tier collateral for banking institutions that want to secure funds for the purpose of backing derivative deals. Banks interested in financing their balance sheets also turn to repo markets.

The Onyx platform allows banks to tokenize the bonds in their possession and lend those tokens out for only a few hours. This time limitation is important because banks are mandated to compute their safety buffers at the end of every workday. Given how high the post-coronavirus requirement to maintain a bigger fraction of assets in highly liquid forms is, it is imperative that borrowed government-issued bond tokens are returned before the business day ends. This keeps those treasury bonds on the balance sheets of the banks that have lent them out through intraday repurchase deals.

The necessary details of each repo deal are contained in a smart contract on the blockchain platform. For example, the lender and borrower agree on the time at which the debt will be settled, as well as for how long the borrower can remain with the borrowed asset, among other details.

J.P. Morgan revealed that it was looking into beefing up the scope of which assets can be tokenized beyond U.S. Treasury bonds. This measure will ramp up the options of assets for those interested in short-term borrowing and lending.

As more multinational financial institutions as well as their clients join platforms such as Onyx, blockchain technology will be well on its way to becoming mainstream, and sector actors such as BIT Mining Ltd. (NYSE: BTCM) will have plenty of clients to serve.

BIT Mining Ltd. (BTCM), closed Tuesday's trading session at $2.13, up 12.1053%, on 2,108,593 volume. The average volume for the last 3 months is 2.039M and the stock's 52-week low/high is $1.09/$14.65.

Workhorse Group Inc. (WKHS)

Green Car Stocks, InvestorPlace, MarketClub Analysis, Schaeffer's, Kiplinger Today, QualityStocks, MarketBeat, StockMarketWatch, StreetInsider, StocksEarning, TradersPro, The Street, Trades Of The Day, Daily Trade Alert, TopPennyStockMovers, TraderPower, BUYINS.NET, Zacks, Wealth Insider Alert, Early Bird, Jason Bond, Cabot Wealth, InvestorsUnderground, PoliticsAndMyPortfolio, StockOodles, The Online Investor,, Profitable Trader Authority, Stock Beast, Wealth Daily, Energy and Capital, The Best Newsletters, Daily Market Beat and The Wealth Report reported earlier on Workhorse Group Inc. (WKHS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

In terms of monthly payments, insurance, maintenance and fuel, the total cost of owning an electric vehicle on a monthly basis is significantly lower than the corresponding cost of an internal combustion engine (ICE) vehicle, according to a recent study.

It isn’t surprising that many motorists get sticker shock when they see the price tag of most electric vehicles. This is understandable given that generally speaking, the most affordable electric vehicle costs approximately twice as much as the most affordable gasoline or diesel-fueled vehicle. However, the recent study suggests that motorists should look at a different metric when comparing ICE vehicles to EVs; that metric is the monthly cost of owning these types of vehicles.

The report shows that when a buyer focuses their attention on the federal tax benefits, fuel savings, and savings on maintenance as well as other monthly costs of an electric vehicle, it becomes undeniable that an EV typically costs less to own and is therefore a more pocket-friendly alternative.

Previous studies had shown that the high up-front cost of buying an EV was worthwhile because the buyer would eventually save as the years go by. However, the study conducted by Energy Innovation & Technology LLC established that in the vast majority of the United States, the cost of owning an electric vehicle was lower than owning an equivalent diesel- or gasoline-powered vehicle. This cost difference starts as soon as you acquire and begin financing the car, not years down the road.

The team of researchers came to these conclusions after focusing on half a dozen EV models, including the Nissan Leaf, Kia Niro EV EX, Hyundai Kona Electric SEL, Volvo XC40 Recharge Plus, and two others. The electric vehicles selected for this study had fossil-fuel equivalents from the same manufacturer. The team then came up with models of the costs of vehicle ownership in each of the 50 states. Those costs included fuel costs, insurance premiums, maintenance and repair costs, car loan repayment, and applicable fees and taxes, as well as the cost of electricity in each state.

Ford’s F-150 Lightning and Hyundai’s Kona Electric SEL were found to be more affordable to own in every single state. This affordability was noticed even when the electric versions cost $10,000 more than their fossil fuel counterparts did. This pattern generally played out across the different vehicle models compared.

The study also listed California, Washington, Oregon, Delaware, New Jersey and Colorado as the best states in which to own an electric vehicle.

As more information becomes available about the cost effectiveness of electric vehicles, manufacturers such as Workhorse Group Inc. (NASDAQ: WKHS) will see sales trending upwards for years to come, especially in the price-sensitive market segments.

Workhorse Group Inc. (WKHS), closed Tuesday's trading session at $3.09, up 3.6913%, on 4,883,049 volume. The average volume for the last 3 months is 4.883M and the stock's 52-week low/high is $2.11/$18.59.

Alliance Resource Partners LP (ARLP)

The Online Investor, Zacks, TradersPro, MarketBeat, The Street,, Dividend Opportunities, TopStockAnalysts, InvestorPlace, TheStockAdvisor, QualityStocks, The Wealth Report, The Motley Fool, Money Morning, StreetAuthority Daily, MarketClub Analysis, Market Intelligence Center Alert, BUYINS.NET, Investing Daily, Daily Wealth, Daily Trade Alert, Rick Saddler, Wealth Insider Alert, The Growth Stock Wire, Trading Concepts, TheOptionSpecialist, TheStockAdvisors, SmarTrend Newsletters, TraderPower, Top Pros' Top Picks, Daily Markets, Trades Of The Day, Eagle Financial Publications, FNNO Newsletters, Greenbackers, Insider Wealth Alert, Short Term Wealth, Investor Update, Leeb's Market Forecast, TheTradingReport, TheStreet Offers, Money and Markets,, StreetInsider and Investment U reported earlier on Alliance Resource Partners LP (ARLP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

In a recent interview, the Minister of Energy in Qatar, Saad Sherida Al-Kaabi, stated that a decline in investments in the production of gas in a bid to reduce carbon emissions had contributed to the United Kingdom’s current fuel crisis. In the interview, Sherida Al-Kaabi stated that Qatar was willing to help England with its crisis as he condemned nations in the West that had demonized gas and oil companies.

The minister explained that the main cause of the current price increase for energy as well as gas prices in various parts of the world, including Europe, could be traced back to even before Ukraine’s invasion. He pointed to an increase in the number of countries calling for the transition into the use of renewable sources of energy and meeting net-zero targets had played a big role in causing this crisis.

These comments were made as a delegation from Qatar, which was led by the Emir, met with UK Prime Minister Boris Johnson to announce that they had entered into a strategic partnership that would involve Qatar investing £10 billion ($1.26 billion) across the United Kingdom.

This investment into the country comes after Ofgem, an energy regulator, signaled that the price cap for energy was expected to increase by about £800 ($1, 012) during winter. This price will be its highest recorded price, with little remedy for the current prices of gas that consumers in the UK are dealing with.

During the interview, the Qatari minister of energy also noted that it wasn’t possible to achieve the transition to the use of renewable energy without using fossil fuels because the sun doesn’t shine all the time and the wind doesn’t always blow. He added that the best fossil fuel available to the world was gas.

Currently, Qatar is one of the biggest suppliers of natural gas to the United Kingdom. The country also has the third-largest proven natural gas reserves around the globe. It ships this fuel in numerous liquefied natural gas tankers to three LNG terminals in Britain.

The minister also stated that in comparison to other nations, the United Kingdom was in much better shape, adding that there wasn’t much Qatar could do to reduce the price of the fuel in the short term. He then noted that the Ukraine war was affecting the fuel’s price, adding that while it would take time to resolve the issue, Qatar was ready to help and would do its best.

Companies such as Alliance Resource Partners LP (NASDAQ: ARLP) also seem poised to benefit from the bullish conditions in the commodities markets.

Alliance Resource Partners LP (ARLP), closed Tuesday's trading session at $19.85, off by 0.100654%, on 1,164,266 volume. The average volume for the last 3 months is 1.164M and the stock's 52-week low/high is $5.96/$20.83.

Freight Technologies Inc. (FRGT)

We reported earlier on Freight Technologies Inc. (FRGT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Freight Technologies (NASDAQ: FRGT) is now trading on the Nasdaq Market. Formerly known as Hudson Capital Inc. (NASDAQ: HUSN), the company changed its name and ticker effective May 27, 2022. According to the announcement, the company will continue to do business under its wholly owned subsidiary’s commercial name: Freight App Inc. (“Fr8App”). The Freight App platform combines technology and artificial intelligence to offer its cloud-based solutions suite that automates the over-the-road transportation process, ultimately decreasing the need for human touch points and reducing load booking time to minutes or even instantaneously. The suite includes Fr8app, a B2B marketplace powered by AI and machine learning that provides a real-time broker portal; Fr8Radar, which offers track-and-trace visibility in real time and all in one screen; Fr8TMS, a transportation management system; Fr8FMS, a fleet management system; Fr8Data, which offers real-time dashboards and reports to shippers and carriers; and Fr8Fleet, which offers private fleet management that enables large corporate shippers to purchase dedicated capacity. “As a hi-tech transportation logistics company 100% in North America, our new Freight Technologies moniker aptly creates a cohesive umbrella for all of our solutions,” said Fr8Tech CEO Javier Salgas in the press release. “In 2022, we are gaining traction as evidenced by our record monthly sales in April, and our positive trend in loads carried this year. We are executing our growth strategy and look forward to delivering in 2022 and beyond.”

To view the full press release, visit

About Freight Technologies Inc.

Freight Technologies is a North American transportation logistics technology platform company focused on U.S.-Mexico-Canada cross-border shipping. Its wholly owned subsidiary, Freight App Inc. (Fr8App), focuses on truckload freight, making shipping simple, transparent and efficient. Fr8App uses its proprietary technology platform to connect carriers and shippers and significantly improve matching and operation efficiency via innovative technologies such as live pricing and real-time tracking, digital freight marketplace, broker, transportation management, fleet management and committed capacity solutions. For more information, please visit

Freight Technologies Inc. (FRGT), closed Tuesday's trading session at $1.8, up 7.1429%, on 32,268 volume. The average volume for the last 3 months is 32,268 and the stock's 52-week low/high is $1.28/$9.90.

TUGA Innovations Inc. (TUGAF)

We reported earlier on TUGA Innovations Inc. (TUGAF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

TUGA Innovations (CSE: TUGA) (FRA: DQ5) (OTC: TUGAF), which is developing solutions for urban mobility challenges with the TUGA, a new type of electric vehicle (“EV”), recently announced the appointment of experienced product developer and mechanical engineer, Samuel Gomez, to the role of head of engineering for Portuguese operations. Gomez brings more than six years of direct experience in vehicle tuning with a focus on ride and handling improvements. In addition, Kraig Shultz has stepped down from his role as chief technology officer, effective immediately, and remains a director of the company. “We are thrilled to have Samuel join us here in Portugal to oversee and assist the engineering team with achieving great product development success. Now that we have formalized our business with headquarters and suppliers here in the area around Lisbon, I want to personally thank Kraig for his enthusiasm and the participation of his team in Michigan for their drive and commitment to help turn TUGA into reality,” said the company’s CEO John Hagie. “We have a great and growing team who are aligned with the goal of seeing TUGA reach commercial production, and I’m truly delighted by the enthusiasm and passion for change this clever little vehicle has been able to ignite.”

To view the full press release, visit

About TUGA Innovations Inc.

TUGA Innovations is a development-stage electric vehicle company undertaking the conception, design and production of specialized EVs to improve the urban mobility experience. The company is looking to reduce urban mobility difficulties by developing a three-wheeled, fully electric fore-and-aft 2-seat vehicle. The vehicle will be no wider than a motorcycle for agility and will have a patent pending expanding rear axle for high-speed stability and a proposed patent pending expandable chassis and body length for passenger comfort. The vehicle will offer advanced connectivity technology to maximize safety, performance, environmental impact, comfort, maintenance, and navigation. The TUGA vehicle is being designed to deliver an estimated 160 km range, have an estimated top speed of 140km/hour with the comforts of a car, and with more protection than a motorcycle in an interchangeable multi-body, multi-function platform. For more information about the company, visit

TUGA Innovations Inc. (TUGAF), closed Tuesday's trading session at $0.12, even for the day. The average volume for the last 3 months is 5,000 and the stock's 52-week low/high is $0.1198/$0.7317.

The QualityStocks Company Corner

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

  • J.D. Power survey reports range was factor most cited in deciding what EV to buy
  • Mullen is making significant strides toward producing vehicles that feature some of the longest ranges available in the EV space
  • Recognizing the critical role of battery and range in the success of an EV, Mullen is exploring other advanced battery technologies

One of the challenges preventing enthusiastic acceptance of electric vehicles is range anxiety, fear that an electric car will run out of battery or fuel before the driver can reach their destination or a charging station. The concern is valid — a January 2022 study reported that the median rage for EV last year was 234 miles ( Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle manufacturer, is focused on improving that number; the company is currently actively testing advanced battery technology which can provide a range of 600-plus miles on a full charge at the pack level ( Mullen Automotive (NASDAQ: MULN) announced results of its solid-state polymer battery testing with the Battery Innovation Center (“BIC”) in Indiana. According to the update, BIC’s testing results show the solid-state polymer cell, rated at 300 Ah and 3.7 volts, tested in at 343.28 Ah at 4.2 volts, exceeding expectation and in line with test tolerance from previous EV Grid test results. Test data collected from both BIC and EV Grid demonstrate an impressive outcome and future for solid-state batteries. It is expected that with this technology, when scaled to the vehicle pack level, a 150-kilowatt hour solid-state battery can, on a full charge, deliver over 600 miles of range for the Mullen FIVE EV Crossover. “I’m impressed with the ongoing performance of the solid-state cell after going thru multiple intense testing sessions from accredited testing facilities,” said David Michery, CEO and chairman of Mullen Automotive. “The battery has performed exceptionally well, and I’m pleased with the results from BIC in Indiana.” To view the full press release, visit

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Tuesday's trading session at $1.4, up 44.8975%, on 312,686,949 volume. The average volume for the last 3 months is 306.068M and the stock's 52-week low/high is $0.52/$15.90.

Recent News

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced that its wholly-owned subsidiary JustCBD will be launching its line of Novel Foods-registered CBD products on Since its entry into the now £700 million CBD market in October 2021, Amazon U.K. has expanded the initial pilot-only program to include vendors who have demonstrated compliance with U.K. CBD Novel Food regulations. Producers awarded U.K. Novel Food authorization must prove the product is safe for consumption and labeled correctly. “With health and wellness playing an increasingly important role in customers’ lives, we are excited to increase the selection of quality CBD products offered to Amazon customers in the U.K.,” said Hussein Rakine, CEO of JustCBD. “The JustCBD team looks forward to working closely with Amazon to expand our product offering to other countries as our partnership and brand presence in the United Kingdom grows.” To view the full press release, visit A study exploring the concentration of marijuana pollen in the atmosphere in the Spanish city of Murcia has discovered that levels of pollen are increasing in the atmosphere. This is a clear indication that the extent of illicit cannabis farming is trending upwards. For decades, scientists have been documenting the amount of marijuana pollen present in the air in order to estimate the extent of illegal marijuana cultivation taking place in different cities, including Cartagena, Lorca and Murcia. This trio of cities is of special interest because they are located along the seashore acting as a border between Spain and Morocco. The researchers were intrigued to discover that, after analyzing the collected pollen, only a small fraction of the pollen could be traced to North Africa. This means that the vast majority of the illicit grows were on Spanish soil and that the country was becoming increasingly less dependent on imported cannabis. Rather, it was now depending on a domestically produced crop to meet the local needs and the needs of the other foreign markets in need of this illicit marijuana.

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.


Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Tuesday's trading session at $1, up 1.0101%, on 965,933 volume. The average volume for the last 3 months is 961,577 and the stock's 52-week low/high is $0.95/$21.45.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

  • Study shows that COVID-19 pandemic has affected mental health of 59% of U.S. population, intensifying already-serious issue
  • CYBN-sponsored feasibility study indicates ketamine-induced changes in brain’s functional connectivity persisted for several days after receiving the substance
  • Kernel Flow pivotal in developing most accurate, effective treatment regimens for patients

The challenges associated with mental-health issues are rising, following the global pandemic. Already a serious problem before COVID-19, mental health has become even more pressing now, with many companies committed to offering relief to the nearly 1 billion people worldwide who deal with mental-health issues. Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to progressing psychedelics to therapeutics, is making major progress in that direction based on pilot results from a recent study evaluating a proprietary neuroimaging technology ( Cybin (NYSE American: CYBN) (NEO: CYBN), today announced the submission of an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”). According to the update, the IND is for Cybin’s phase 1/2a first-in-human clinical trial evaluating CYB003, a proprietary deuterated psilocybin analog, for the treatment of major depressive disorder (“MDD”). “Following the successful completion of our IND-enabling work just last month, we are very excited to have reached this major milestone toward advancing CYB003 into clinical development so quickly. Based on preclinical studies, our proprietary psilocybin analog has the potential to offer numerous advantages over classic psilocybin with the potential to ultimately provide better outcomes for people suffering with MDD,” said Cybin CEO Doug Drysdale. “This FDA submission is the next major step in the advancement of CYB003, and we continue to work tirelessly to bring this innovative therapeutic option to people as quickly as possible. We look forward to continuing to work with the FDA to initiate the phase 1/2a trial in mid-2022.” To view the full press release, visit In today’s world, we spend most of our day in front of a screen, be it a phone, laptop or computer. While what we’re doing may be productive, overusing technology may have a negative effect on mental health. This is why undergoing a digital and/or social detox to help disconnect from technology may be beneficial. Here’s what you need to know about media detoxes. What are social media and digital detoxes, and why should you detox?
A social media detox is when an individual refrains from using or engaging with social media for a set period, or indefinitely, to improve their well-being and mental health. A digital detox is when someone totally refrains from or intentionally decreases the amount of time spent using all electronic devices, including tablets, TVs, computers and smartphones. During a digital detox, individuals usually avoid watching TV, playing video games, and sending text messages and emails as well as the use of all other electronic devices. Unfortunately for some people who have already been diagnosed with mental illness, a digital detox may be too little, too late. Such people may in the future be better served by the novel treatments that are currently being developed by many companies, including Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), which is evaluating the use of psychedelics in the treatment of mental health.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin ( Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Tuesday's trading session at $0.68, up 5.0842%, on 399,575 volume. The average volume for the last 3 months is 395,840 and the stock's 52-week low/high is $0.3903/$3.38.

Recent News

Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF)

The QualityStocks Daily Newsletter would like to spotlight Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF).

Eat Well Group (CSE: EWG) (OTC: EWGFF)a publicly traded investment company, has released an update regarding the anticipated timelines for the filing of its audited annual financial statements for the year ended Nov. 30, 2021, as well as other required documents, including the related management’s discussion and analysis and certificates of its CEO and CFO. The announcement noted that additional delays have taken place, although the company and its auditors continue to work diligently to file the required documents as soon as possible. According to the most recent estimates, the company plans on filing the information by June 10, 2022. In the announcement, Eat Well Group reiterated that, under the current management cease trade order (“MCTO”) issued by the British Columbia Securities Commission, its chief executive officer and chief financial officer are not allowed to trade in securities of the company. The company also confirmed that there have been no material changes to the information contained in the default announcement originally issued in March; that there have been no failures by the company to fulfill its stated intentions with respect to satisfying the provisions of the alternative reporting guidelines under NP 12-203; that there has not been, nor is there anticipated to be, any specified default subsequent to the default which is the subject of the default announcement; and there is no other material information concerning the affairs of the company that has not been generally disclosed. To view the full press release, visit

Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF), headquartered in Vancouver, British Columbia, is a publicly traded vertically integrated plant-based foods company combining the best of agribusiness, foodtech, and CPG brands to supply the world with innovative, delicious, and better-for-you foods. The company supplies Beyond Meat, Ingredion, Nestle, General Mills and more. It is on track to generate $60 million in revenue for 2021 and is projecting $100 million in revenue for 2022.

Eat Well’s management team has an extensive record of sourcing, financing and building successful companies across a broad range of industries and maintains a current investment mandate on the health and wellness industry. The team has financed and invested in early-stage venture companies for more than 25 years, resulting in the ability to construct a portfolio of opportunistic investments intended to generate superior risk-adjusted returns. Eat Well’s strategic advisory board includes pioneers in the plant-based foods industry, including HRH Prince Khaled bin Alwaleed bin Talal Al Saud, Founder and Chief Executive Officer of KBW Ventures, and Jeff Dunn, CEO of Bolthouse Farms who previously held senior leadership positions at both Campbell Soup Company and The Coca Cola Company.

The company’s plant-based investment thesis is centered on growing its seed-to-market operations, which include raw ingredients, processing, pulse fractionation, unique IP and premium consumer packaged goods (CPG). Eat Well Group is building a unique ecosystem that can supply these essential cornerstone needs for society. The company has plant-based foods and nutrition experts specializing in the latest science and original thinking for what consumers want most – high quality and affordability in healthy, clean and simple products.

Eat Well focuses on intellectual property, product portfolio development and long-term value creation for stakeholders in a rapidly expanding industry. As an emergent sector globally, plant-based foods represent a double-digit annual growth category, with more than 35% of the world’s supply of pulse proteins coming from Canada.


On July 31, 2021, Eat Well Group acquired Belle Pulses Ltd., one of the top pulse processors in Canada. Belle Pulses has been operating for over 40 years and had over $60 million in sales in 2020. The company counts a broad range of customers in over 35 countries, including global strategic food companies and major ingredient distributors. Currently, Belle produces nearly 100,000 tons of fully traceable seed and product, yielding over 26,000 tons of pure plant protein.

Eat Well also owns 100% of Sapientia Technology Inc. Led by Dr. Eugenio Bortone – one of the world’s preeminent food scientists and extrusion processing experts and the inventor of Frito-Lay’s Twisted Cheetos – Sapientia has filed four patents around the “protein curl” and crispy-puff-style snack. By focusing on texture and crunch, Sapientia’s patents solve one of the major problems that large scale snack food companies have struggled with for years – how to offer appealing texture and flavor in a guilt-free, not fried, natural and healthy alternative to the majority of snack food products available today.

Eat Well owns a 51% share of Amara Organic Foods, with an option to acquire additional ownership up to 80 percent. Amara, one of the fastest-growing baby food brands in America, is a food technology company that uses science and proprietary IP that locks in taste and texture to make healthy, organic, non-GMO, plant-based, convenient baby and children’s food possible for modern-day families. From baby food to toddler food and beyond, Amara is driven by the belief that setting kids on the right path from a young age will help them live better, feel better and think better for the rest of their lives. Amara’s revenues have grown by more than 400% since January 2021, and the brand’s success has drawn media coverage from business news outlets including Forbes and TechCrunch.

Market Outlook

According to an August 2021 report from Bloomberg Intelligence, the plant-based foods market is expected to experience explosive growth, comprising up to 7.7% of the global protein market by 2030 at a value of over $162 billion, up from $29.4 billion in 2020. Bloomberg notes that plant-based alternatives are here to stay, and that consumption will grow rapidly. Plant-based food sales in 2020 grew twice as fast as overall food sales, according to Polaris Market Research.

Pulse proteins (fava, yellow pea, etc.) are a foundational ingredient to most plant-based foods due to their high protein content and their readily available, affordable supply.

Many analysts view the food tech market as similar to the early days of the Internet in that plant-based foods represent a worldwide secular trend of steady growth and potential that will revolutionize the way society functions and people experience nutrition.

The sector continues to experience significant M&A transactions. Recently, Sol Cuisine was acquired by PlantPlus Foods LLC, a major South American protein producer, in an all-cash transaction valued at approximately $126 million, or 6x revenue.

Management Team

Marc Aneed is President and Director of Eat Well Group. His 20-year career in CPG started at The Quaker Oats Company/PepsiCo, where he worked on iconic brands like Gatorade. He previously was at Glanbia PLC, a global nutrition company, where he led Amazing Grass, a leading plant nutrition and supplement company with over $100 million in retail sales. He also led Glanbia’s Sports Nutrition brands in North America with over $750 million in retail sales. Mr. Aneed has launched dozens of successful consumer products, driving over $1 billion in collective retail sales.

Mark Coles is the company’s Chief Investment Officer. He is a veteran CPG senior executive specializing in the plant-based foods sector. For the past decade, Mr. Coles has spearheaded global plant-based start-up initiatives, culminating in a 2020 acquisition by an international New York Stock Exchange-listed food ingredient company. He has over 25 years of experience in CPG-focused strategy, mergers and acquisitions and project financing.

Patrick Dunn is Eat Well Group’s Vice President, Finance. He is the founding partner of Dunn, Pariser & Peyrot and has a track record of building highly successful agribusinesses throughout North America and other international markets. As a testimony to his business portfolio work, Mr. Dunn and his firm have won multiple industry awards for accounting, finance and business management.

Barry Didato is the company’s Vice President, Strategy. He is focused on the development of strategic revenue channels, sales partnerships, and international distribution for Eat Well Group. Mr. Didato brings extensive strategic sales capabilities and an extensive network of contacts in the industry to the company. Prior to joining Eat Well Group, he served for over 18 years as a senior advisor for several ultra-high net worth family offices and numerous innovative wellness, nutrition, medical, and food businesses.

Strategic Advisory Board

HRH Prince Khaled bin Alwaleed bin Talal Al Saud, Founder and Chief Executive Officer of KBW Ventures, is a firm supporter of clean energy and the humane treatment of animals. He is also a vocal supporter of the private sector in the Middle East. A member of the Saudi Arabian Royal Family, Prince Khaled was born in Stanford and spent his youth in Riyadh under the mentorship of his father, philanthropist HRH Prince Alwaleed bin Talal Al Saud, Chairman of Kingdom Holding Company. He is also the Founding Chairman of KBW Investments and serves across several boards. He invests in an array of successful but diverse global businesses – from promising technology startups to established companies. Today, with holdings on three continents, Prince Khaled stands at the gateway between the Middle East’s evolving economies and the Western world. Consistently, Prince Khaled’s focus is on ventures and ideas at the intersection of innovation and economic growth.

Jeff Dunn has over 30 years of experience in agriculture and packaged food, including senior leadership positions with Bolthouse Farms, Campbell Soup Company and The Coca Cola Company, among others. He is an Operating Partner at Butterfly and focuses primarily on the agriculture & aquaculture and food & beverage product sectors. Prior to joining Butterfly, Mr. Dunn was the President of the Campbell Fresh division of Campbell Soup Company from 2015 to 2016, where he was in charge of building Campbell’s scale and accelerating its growth in the rapidly expanding packaged fresh segments and categories across the retail perimeter.

Eat Well Investment Group Inc. (OTC: EWGFF), closed Tuesday's trading session at $0.25706, up 11.7652%, on 9,610 volume. The average volume for the last 3 months is 9,610 and the stock's 52-week low/high is $0.186/$1.00.

Recent News


The QualityStocks Daily Newsletter would like to spotlight SPYR Inc. (OTCQB: SPYR).

SPYR (OTCQB: SPYR), dba SPYR Technologies, a technology company, has signed a material definitive agreement to acquire GeoTraq Inc. from NASDAQ-traded JanOne Inc. (NASDAQ: JAN). According to the announcement, GeoTraq develops and manufactures self-contained and ultra-small Mobile Internet of Things (“IoT”) modules that can be used for asset tracking and location-based services, as well as sensor modules for remote monitoring. GeoTraq Mobile IoT modules are small, offer a long battery life, consume low power and provide global LPWAN connectivity. Because the modules work right out of the box, users eliminate the hassle and cost of designing and building a printed circuit board for mounting. In addition, the modules achieve extremely accurate indoor and outdoor positioning capability without any global positioning system (“GPS”) or global navigation satellite system (“GNSS”); they only use LTE radio by cellular tower triangulation. In addition, SPYR subsidiary, Applied Magix Inc. is evaluating the possibility of adding health and wellness products to its product category portfolio. The trillion-dollar global market is ripe for more personalization in the areas of health, fitness, nutrition, appearance, sleep and mindfulness, which is where Applied Magix sees opportunity. “While home and car are important to most people, really the most important thing to most people should be, and is, their health,” said Applied Magix CEO Dr. Harald Zink in the press release. “We are excited about exploring which products to add to our health and wellness line. . . . Technology over the past few years has made health and health monitoring easier and more accessible than ever, and we are really excited about adding this most important category to Applied Magix, which will be accessible under a new Health section on our website.” To view the full press releases, visit and

SPYR Inc. (OTCQB: SPYR), dba SPYR Technologies, is a technology company which, through its Applied MagiX Inc. subsidiary, develops and resells Apple®-ecosystem-compatible products with an emphasis on the growing, multibillion-dollar Internet of Things (IoT) Smart Home and Connected Car markets.

SPYR continues to identify and target acquisitions with an aim of growing its footprint in the industry and expanding the products it offers consumers, including companies developing artificial intelligence and smart-technology products. In 2020, SPYR acquired Applied MagiX Inc., a registered Apple developer and reseller of Apple ecosystem compatible products with an emphasis on the smart home market, as a wholly owned subsidiary. Applied MagiX operates in the IoT market and, more specifically, the segment of the market related to the development, manufacture and sale of devices and accessories specifically built on Apple’s HomeKit® framework. These products work within the Apple HomeKit ecosystem and are exclusive to the Apple market and its consumers.

Initially, while working to develop, manufacture and sell its own line of branded products, Applied MagiX will be sourcing HomeKit products and accessories from worldwide manufacturers, vetting and selecting best-of-breed products, selling them directly to consumers and supporting them. The company focuses on Apple consumers – a target market with higher disposable income and a demonstrated willingness to pay a premium for quality products. On average, Apple product users spend roughly twice as much on technology as other smartphone users. Those who purchase smart home products spend more than $3,000 on average.

By creating smart hardware and software solutions exclusively for Apple consumers, SPYR addresses a problem faced by that market – having few “smart” devices that integrate with Apple’s HomeKit, despite being the most affluent and loyal consumers of tech products.


The company’s Applied MagiX subsidiary offers multiple product lines to its target markets. First, the subsidiary is a reseller of third-party manufactured Apple HomeKit and Apple CarPlay compatible products. HomeKit comes pre-installed on every new iPhone, while the CarPlay platform is licensed by all major auto manufacturers. Applied MagiX identifies white label products, applies the company’s branding, improves the software and sells these improved products to consumers. Finally, Applied MagiX is developing its own proprietary line of smart home and connected car products, including Apple-compatible home cameras, sensors and alarms, as well as additional Apple-compatible smart car products in the iOS ecosystem.

Among the subsidiary’s products sold to consumers are:

  • The MagixDrive Wireless CarPlay adapter, which allows users to access CarPlay wirelessly using their iPhones
  • The HomeKit Secure Video Camera with iCloud Storage
  • The Multipurpose Sensor with Alarm
  • The Environment and Motion Sensor
  • The Window and Door Contact Sensor

Market Outlook

According to Statista, the global smart home market is expected to generate revenue of more than $104 billion in 2021. The market is forecast to hit more than $187 billion in revenue by 2025, recording a CAGR of 15.75 percent.

The number of active households in the worldwide smart home market is expected to reach nearly 500 million by 2025. Household penetration is just over 12 percent in 2021 and is projected to nearly double by 2025 to more than 22 percent.

Allied Market Research valued the global connected car market at more than $63 billion in 2019 and projected a CAGR of 17.1 percent, which would push revenue to more than $225 billion by 2027. Allied identified rising consumer demand for connectivity solutions, surging need for constant connectivity, increasing dependency on technology and an upsurge in tech-savvy population as key factors driving the projected growth of the connected car market.

Management Team

James R. Thompson is the CEO, President and General Counsel of SPYR. Over the past 28 years, Mr. Thompson has deftly managed a colorful spectrum of legal clients and situations. In the process, he has helped many companies – both large and small – thrive. Now he welcomes the challenge to take the company and his career in an entirely new direction. A native of Philadelphia, he holds a J.D. from Rutgers University and a Bachelor of Science from the University of Denver.

Jennifer Duettra is the Executive Vice President of SPYR. She brings a great deal of knowledge in mobile gaming and pop culture to the company. She is an attorney and was thrilled by the prospect to combine her law experience with a chance to be creative. She is a native of Colorado and received her Bachelor of Arts in Political Science and Speech Communication from Colorado State University. She holds a J.D. from Harvard University.

Trang Nguyen is the CFO of SPYR. From 2019 to 2020, she served as the Financial Reporting Manager for Del Taco, where she was responsible for the preparation and filing of periodic financial reports with the U.S. Securities and Exchange Commission. From 2016 through 2019, Ms. Nguyen was Accounting Manager for Pinnacle Tax Accounting in Los Angeles, California. She was a part of Ernst & Young’s audit team in Los Angeles from 2006 to 2008, leading engagements on interim and year-end ad SOX 404 auditing procedures for major enterprise accounts. Ms. Nguyen holds a Bachelor of Art, Business Economics (Minor in Accounting) from the University of California, Los Angeles. She is a certified public accountant with an inactive license.

Dr. Harald Zink is the CEO, Founder and Chief Product Architect of SPYR subsidiary Applied MagiX. Prior to founding Applied MagiX, he was Director of Technologies and later Vice President of Technologies at Sarkissian Productions in Los Angeles. He also served as Director of Technologies at SMZ Technologies and, for more than 17 years, as Macintosh Technology Consultant to The Walt Disney Studios in Burbank, California. He speaks five languages and holds degrees from the University of California, Riverside.

Kelly Clark is the COO of Applied MagiX. Before joining the subsidiary, he worked as Vice President of Sales Operations at TruClear Global. Prior to that, Mr. Clark was Senior Director of Program Management at Pacific Group Ventures and Operations Manager at Barco. He has also held operations management positions at Deluxe Digital Studios and Sony Pictures Entertainment. Mr. Clark holds a bachelor’s degree in international business from the University of Southern California.

SPYR Inc. (OTCQB: SPYR), closed Tuesday's trading session at $0.035, up 0.143062%, on 2,725,391 volume. The average volume for the last 3 months is 2.725M and the stock's 52-week low/high is $0.02355/$0.1005.

Recent News

Silo Pharma Inc. (OTCQB: SILO)

The QualityStocks Daily Newsletter would like to spotlight Silo Pharma Inc. (OTCQB: SILO).

Scientists at the University of Colorado Anschutz Medical Campus and the University of California Davis are planning to screen compounds in an effort to find new non-hallucinogenic treatments for substance-use disorders. This research will be funded by a $2.7 million grant that was awarded to the institutions by the National Institute on Drug Abuse. The studies are based on evidence from animal and human tests which suggest that psychedelics possess brain-altering effects that could be beneficial in the treatment of addiction. Prior research has also found that psychedelics rewire some regions in the brain that are involved in post-traumatic stress disorder, substance abuse and depression. UC Davis associate professor David Olson, from the departments of biochemistry, chemistry and molecular medicine, hopes to find similar effects among compounds that don’t possess the hallucinogenic effects of substances, such as LSD. Olson refers to these compounds as psychoplastogens because they can alter the brain. The government-funded research will be a welcome addition to the privately funded studies undertaken by entities such as Silo Pharma Inc. (OTCQB: SILO) in a bid to advance psychedelic medicine. On May 19, 2022, Silo Pharma (OTCQB: SILO) announced that The Translational Psychedelic Research (“TrPR”) Program at UCSF (University of California San Francisco) had “successfully dosed [with psilocybin] patients suffering from Parkinson’s disease.” TrPR connects researchers and medical professionals studying how psychedelics, including psilocybin, ketamine, etc., affect brain functions and other organ systems. Silo Pharma focuses on palliative uses of psychedelics for “PTSD, Parkinson’s, and other rare neurological disorders.” In teaming up with TrPR. Silo is exploring psilocybin’s anti-inflammatory possibilities in patients exhibiting signs of Parkinson’s Disease. 

Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry.

Silo is committed to developing innovative solutions to address a variety of underserved conditions. Combining Silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space.

Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves.

Silo recently engaged Donohoe Advisory Associates LLC for consulting and advisory services in connection with the potential uplisting of Silo’s common shares to the Nasdaq Stock Market.


Silo has entered into research agreements and partnerships with multiple leading medical universities.

The company is involved in a sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action. The investigator in the Netherlands is acquiring the substances for the study and will then finalize the documentation to submit to the ethics committee.

Additionally, in June 2021, Silo announced its entry into a scientific research agreement with the University of California San Francisco (UCSF). The agreement will leverage four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF.

Silo also recently extended its exclusive option agreement with the University of Maryland, Baltimore (UMB) to explore a novel invention generally known as joint-homing peptides. These peptides are being developed for use in the investigation and treatment of arthritogenic processes and can be used for enhanced targeting of therapeutic agents.

This agreement includes the study of two separate peptides. The first is an option and study for the treatment of arthritis. The second is a patented licensed peptide for the central nervous system, with an initial study for MS autoimmune diseases, in addition to rheumatoid arthritis. Animal studies are underway for both initial indications relating to the UMB agreement, with the potential for studies evaluating additional indications in the future.

Finally, Silo signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD. Both candidates are currently being tested in mice and have already provided early data.

In addition to its university partnerships, Silo entered a joint venture agreement with Zylo Therapeutics Inc. (“ZTI”) focused on the development of ketamine and psilocybin using ZTI’s Z-Pod™ technology for the transdermal time released delivery of therapeutics. In November 2021, the company announced ZTI’s reception of its first ketamine shipment and initiation of loading ketamine into its Z-Pod technology. In a news release, Eric Weisblum, CEO of Silo, called the development an “important milestone” that will help the company “study the benefits of slow-release transdermal release of Ketamine.”

Market Overview

According to Coherent Market Insights, the fibromyalgia treatment market was valued at $2.78 billion in 2018 and has a projected CAGR of 3.3% over the forecast period 2018 to 2026. Fibromyalgia is a condition that causes pain all over the body, sleep problems, fatigue, and emotional and mental distress.

The global PTSD therapeutics market is expected to reach $10.68 billion by 2026 with a CAGR of 4.5% during the forecast period from 2018 to 2026, according to a report by Credence Research. Growing prevalence of PTSD is the chief factor driving the global treatment market. Increases in events such as wars, combat, and interpersonal violence has been a major contributing factor. Other factors like growing emphasis on rehabilitation initiatives by governments for treating their war veterans has also been facilitating the increase in demand for PTSD therapeutics.

Fortune Business Insights reports the global Parkinson’s disease treatment market is predicted to grow to $8.38 billion by 2026, with a CAGR of 8.1% during the forecast period. Parkinson’s is a neurodegenerative disease of the central nervous system which primarily affects the brain, causing uncontrollable shaking and tremors, difficulties in balance and restricted body movement making it difficult for the person to function or perform a daily routine.

Management Team

Eric Weisblum is CEO and founder of Silo Pharma. He has over 25 years of Wall Street experience, most recently in the biotechnology sector. He has served on the board of Aikido Pharma and was the president of Sableridge Capital. He has a proven track record in licensing therapeutic assets and assisting in their development. He brings to the company nearly 20 years of expertise in structuring and trading financial instruments. He holds a bachelor’s degree from the University of Hartford’s Barney School of Business.

Dr. Kevin Muñoz was appointed to the Silo board of directors in October 2020. He teaches biomedical sciences and medical intervention for the Passaic County Technical Institute. He previously served as Director of Operations at Physical Medicine and Rehabilitation. He began his career with Harlem Health Promotion Center in New York City as a research assistant. He earned a bachelor’s degree from the University of Michigan and a Doctor of Medicine from Xavier University School of Medicine.

Josh Woolley, M.D., Ph.D., is a Scientific Advisor for Silo. He is an associate professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco. He is also a psychiatrist on staff at the San Francisco Veterans Affairs Medical Center. He is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders Laboratory. He received both his M.D. and his Ph.D. in Neuroscience from UCSF, where he completed his psychiatry residency training.

Charles Nemeroff, M.D., Ph.D., is a Scientific Advisor for Silo Pharma. He directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. He was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine. He received his M.D. and Ph.D. in neurobiology from the University of North Carolina School of Medicine.

Silo Pharma Inc. (OTCQB: SILO), closed Tuesday's trading session at $0.145, even for the day, on  volume. The average volume for the last 3 months is 8,688 and the stock's 52-week low/high is $0.12/$0.2979.

Recent News

Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF)

The QualityStocks Daily Newsletter would like to spotlight Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF).

Playgon Games (TSX.V: DEAL) (OTCQB: PLGNF) (FSE: 7CR), a propriety SaaS technology company delivering mobile-first live-dealer technology to online gaming operators globally, is reporting its first quarter 2022 financial numbers; the report is for the quarter ended March 31, 2022. Highlights of the report include company revenues of $140,877, which came from Playgon’s Live Dealer platform. The company noted that it saw increased player betting throughout the quarter, a strong indicator for future revenue growth. In addition, Playgon observed an increase in player win percentage resulting in reduced house margins. The company also reported loss for the quarter of $3,899,555, a slight increase from its March 31, 2021, number; Playgon also had cash on hand of $2,486,326 at the end of the quarter. In addition, operational highlights for the quarter included Playgon entering into a multijurisdictional software licensing and distribution agreement with Relax Gaming, its fourth European aggregator. The company also onboarded nine additional operators, bringing total operator count to 35, and appointed  industry veteran Bobby Soper to its board of directors. “Q1 was another important quarter for Playgon,” said Playgon Games CEO Darcy Krogh in the press release. “We continued to see increased player activity throughout the quarter, and we exited with a healthy pipeline of new opportunities, which we expect to announce in due course. This will include entry into new markets for the company's innovative mobile live dealer product that we are excited to enter.” To view the full press release, visit

Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF) is a SaaS technology company focused on developing and licensing digital content for the growing global iGaming market. The company provides a multi-tenant gateway that allows online operators the ability to offer their customers innovative iGaming software solutions. Its current software platform includes Live Dealer Casino, E-Table Games and Daily Fantasy Sports. Seamless integration at the operator level allows customer access without requiring the sharing of any sensitive customer data. Playgon games run on any browser and any device as fast and secure as a native app, without requiring any app store download. All that’s needed is a stable internet connection. The gaming experience is identical across all mobile devices. As a true business-to-business digital content provider, the company’s products are scalable turnkey solutions for online casinos, sportsbook operators, location-based operators, media groups, and big database companies.

Playgon’s proprietary technology provides digital games for online gambling sites and mobile device apps, with the company licensing its mobile live-dealer technology to online gaming operators worldwide. Playgon combines high definition live streaming dealers with state-of-the-art augmented reality betting to provide the most authentic casino experience, live from Las Vegas. Playgon’s mobile platform features popular table games, all optimized for one-handed play on mobile devices.

The COVID-19 pandemic has accelerated an already existing shift away from location-based casinos to online gambling. At the same time, the proliferation of mobile devices has provided players with new access to betting. A younger, tech-savvy consumer demographic is driving adoption of digital gaming globally. To meet this demand, Playgon has launched a studio with 10 gaming tables from which its live dealer streaming video originates. The company’s platform is live with multiple online casino operators through four aggregator clients in South Africa and Europe, and commitments are coming in from more.

Playgon plans to expand the studio to 25 tables in the near term and is working to establish a U.S. strategy. The company will continue to expand licensing of its live dealer games to iGaming operators worldwide under a SaaS license agreement. As a B2B software supplier, Playgon avoids player acquisition costs.


Live Dealer Casino

Playgon offers the first and only Live Dealer Casino streaming live from Las Vegas. The company brings cutting-edge handheld features and functionality to the mobile generation of gaming enthusiasts who demand a world-class gaming experience on all devices. Playgon’s Blackjack delivers the look and feel of location-based casino tables with features providing players with the most unique user experience. The company’s true-to-life Roulette offers players a clear and uninterrupted view of the dealer, wheel, ball, bets, results, trends and statistics. Players can strategize, place multiple bets, track results and review trends without ever losing focus of the game.

Playgon’s traditional Baccarat and proprietary Tiger Bonus Baccarat™ prove their worth by not only recognizing the need for a prominent product, but by adding elements which separate them from the pack without removing their authenticity. The games mix advances in technology with the traditional game attributes that have resonated and captivated players for hundreds of years.

eTable Games

To lead the rise of mobile-first gaming, Playgon developed a user experience perfected for one-handed play. Providing this next evolution in gaming technology ensures the company’s client operators loyalty from existing customers and is a powerful strategy to attract and retain new players. Playgon’s VEGAS LOUNGE™ brings together an innovative mix of games, technology and gameplay that offers players an authentic experience and real Las Vegas casino fun every time, everywhere.

Daily Fantasy Sports

Playgon’s Daily Fantasy Sports (DFS) are a subset of fantasy sport games which typically target a younger demographic. DFS provides iGaming operators a turnkey fantasy sports platform that can quickly go to market, integrate with the operator’s existing operations and services, and be customized to match and enhance the operator’s brand. The platform is mobile and desktop friendly, built for regulated market environments, and allows operators to monetize users through a network of shared liquidity.

Market Outlook

Online casinos and sports betting sites/apps are increasingly adding market share to traditional location-based casinos. This trend is only expected to accelerate as millennials reach their peak earning years and Gen Z youth begin to complete their education and move into careers. These generations are completely comfortable with online recreation, as well as tech like digital wallets and digital gameplay that underpins Playgon Games. The company has been described as “Netflix + Vegas, all in one.”

The online gambling market is slated to reach a value of $127.3 billion by 2027, according to Grand View Research, with much of the growth expected from the U.S. and Asia. Even Europe, the most mature gaming market, is expected to grow at a rate of 20-25 percent year over year. The current global online Live Casino TAM is estimated at about $6 billion annually, and revenue is forecast to reach more than $8 billion by 2023 and more than $13 billion by 2027.

Management Team

Darcy Krogh is CEO of Playgon Games. He is a veteran of the iGaming industry with over 20 years of experience. In 1999, he co-founded Chartwell Technology Inc., which pioneered the development of browser-based digital content for the iGaming industry. After that company was sold to Amaya Gaming Group, he served as VP Business Development with Amaya. In 2016, he started Playgon Games (formally Global Daily Fantasy Sports Inc.) as President and CEO. His experience in the online gaming industry includes sales and marketing, relationship management, corporate finance, M&A, and strategic corporate development.

Guido Ganschow is President of Playgon Interactive. He has more than 12 years of experience in creating real-time Live Dealer technology and platforms and was the co-founder and Creative Director for a Macau-based casino consortium. Between 2008 and 2014, he successfully created and established Live Dealer platform businesses in Asia and Europe, and executed commercial partnerships, sales, and integration of the Live Dealer solution with major global gaming brands, including Ho Gaming Group, Chartwell Technology and Amaya Gaming Group.

Steve Baker is COO of Playgon. He is a former VP Operations for Shaw Communications, where he was directly involved in video streaming, home entertainment, new products, sales and M&A. He oversaw revenue growth from $300 million to $2.8 billion and employee growth from 350 to 13,000. He has broad experience and a proven record in development and implementation of cost effective and efficient growth strategies transitioning businesses from development to operations.

Harry Nijjar is CFO of Playgon Games. He is currently a Managing Director with Malaspina Consultants Inc. and provides CFO and strategic financial advisory services to his clients across many industries. This experience has allowed him to help his clients successfully navigate the regulatory and financial environments within which they operate. Mr. Nijjar holds a CPA-CMA designation from the Chartered Professional Accountants of British Columbia.

Playgon Games Inc. (PLGNF), closed Tuesday's trading session at $0.05354, even for the day, on  volume. The average volume for the last 3 months is 429 and the stock's 52-week low/high is $0.0416/$0.406.

Recent News

Prime Harvest Inc.

The QualityStocks Daily Newsletter would like to spotlight Prime Harvest Inc.

Prime Harvest Inc., based in San Diego, California, is a technology-focused, full-service cannabis company with horizontally diversified operations spanning various segments of the cannabis value chain, from licensing acquisition and compliance management to direct-to-consumer operations. The company is leveraging a long-term strategy of investing in the growth and scale of licensed assets anchored by the power of data-driven technology to expand its footprint throughout California.

Sustainability is key to Prime Harvest’s corporate vision. The company aims to ensure that the communities it serves capture their fair share of the fruits of the industry’s growth, including financial profit, employment opportunities, environmental enrichment and impactful innovation through R&D and education.

The company’s mission is to appeal to the ethos of the cannabis consumer by setting a new operational standard emphasizing accountability, sustainability and community. With this commitment, Prime Harvest continues to work toward positively affecting millions of lives through the creation of a world-class platform that caters to strengthening the commercial cannabis pipeline.

Jaxx Cannabis

Jaxx Cannabis is the flagship brand in Prime Harvest’s portfolio. Through Jaxx Cannabis, the company aims to use technology to facilitate a true customer-centric culture while enhancing the overall craft cannabis experience. Jaxx features an expertly curated selection of premium products from some of the most respected brands in the thriving California market.

Key values serving as the foundation of Jaxx Cannabis include:

  • Creating and nurturing a welcoming culture for all
  • Unlocking the true potential of customer value
  • Being innovative in uncovering new ways to grow both the company and the industry
  • Meeting the wants and needs of consumers to promote profitability
  • Remaining accountable for the results of its operations

It is these values that differentiate Prime Harvest and Jaxx Cannabis in the California cannabis sector.

Brand Partnerships

Prime Harvest works diligently to establish strong alliances with complementary brands that are in alignment with its culture and values. Through a combination of deliberate foresight and strategic action, the company seeks to grow existing cannabis brands and continuously discover new, high-potential performers that are primed for long-term success.

These partnerships enhance Prime Harvest’s efforts to transform the world’s cannabis access and bring its consumers high-quality products that are fair for both people and the planet.


Prime Harvest remains committed to the goal of creating a more sustainable environment, now and in the future. Concern for human beings and the environment can be observed in every facet of its operations, including its ongoing R&D activities dedicated to exploring methods of reducing and repurposing waste into composite materials and exploring the potential of the hemp plant for industrial and wellness contributions.

The company is a proud member of the Community Alliance Program, a foundation that seeks to make a difference in local communities by providing financial assistance for educational programs, housing homeless veterans, creating urban farms, and holding local arts initiatives for children and adults. The program also helps explore the natural healing attributes of medical cannabis through research, development, clinical trials, and advocating for the safe access of cannabis to those in need.

Market Overview

Ongoing changes in U.S. state government policies toward cannabis are expected to cause demand for legal marijuana to surge. In addition, the number of indications for which medical marijuana is prescribed continues to increase. These factors are expected to rapidly boost legal sales of cannabis products.

Legal sales across the U.S. hit a record of $17.5 billion in 2020, marking an increase of 46% over 2019, according to Forbes. This strong growth is expected to continue. According to a Grand View Research report, the global legal marijuana market is forecast to grow at a CAGR of 26.7 percent from 2021 to 2028.

California – Prime Harvest’s home state – has consistently led the pack in terms of U.S. cannabis sales. The Motley Fool pegged cannabis spending in the Golden State at $3.8 billion in 2020, more than doubling the second state on its list.

Leadership Team

The Prime Harvest team is composed of true experts in their respective fields focused on building a world-class organization capable of driving the cannabis industry and movement forward.

E. Duane Alexander is the company’s Founder and CEO. He brings to the team more than 25 years of real-world, hands-on cannabis retail, marketing and commercial operations experience. Mr. Alexander has championed 40+ cannabis license applications throughout the western U.S. to date.

John Wilczak is the COO of Prime Harvest. He has 30+ years of executive management, strategy development & configuration experience with GE, pharmaceutical and agriculture companies. Mr. Wilczak is a Brown & Columbia MBA with vast knowledge of technology driven intellectual properties.

Andrea Jenson is the Chief Financial Officer of Prime Harvest. As CFO, she is responsible for all the company’s financial functions, including accounting, corporate finance and investor relations. Her career spans more than 20 years of varied experience in financial management, business leadership and financial strategy.

John Kazanjian is the VP of Business Development of Prime Harvest. He has worked over 40 years in business operations, brand marketing, sales and investor/lender communications. Mr. Kazanjian earned his B.S. from Rutgers University and his MBA from Harvard University.

Johann Balbuena is the Chief Marketing Officer of Prime Harvest. She has more than six years of experience in California cannabis licensing acquisition and compliance management. Ms. Balbuena has led multimedia production and content marketing efforts for the likes of the Social Club TV app, The Emerald Cup, High Times, Weedmaps and Synergy.

Recent News



The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX, Inc. (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, will announce Q4 and Full Year earnings for 2021 this Monday, June 6th, 2022. Conference Call: SRAX's Founder and CEO Christopher Miglino, and CFO Michael Malone will provide an operational and financial summary for Full Year 2021 on a video call, with a live question and answer session, on Monday, June 6th, at 10:30 am ET / 7:30 am PT. To register for the live webcast and view the presentation, please sign up here: To access the conference by phone: Dial in: +1 346-248-7799, Meeting ID: 92139622922, Passcode: 432792

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.


BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.


Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Tuesday's trading session at $3.44, off by 3.0986%, on 27,595 volume. The average volume for the last 3 months is 27,595 and the stock's 52-week low/high is $3.00/$7.29.

Recent News

Knightscope, Inc. (NASDAQ: KSCP)

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc. (NASDAQ: KSCP).

Knightscope, Inc. (Nasdaq: KSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, today announced the deployment of a K5 Autonomous Security Robot (ASR) in a popular northern California park. A parks and recreation organization that serves a large, densely developed suburban population will be using the ASR to patrol the area with specific mission of protecting the quality of life and environment of the community. The Huntington Park, California, chief of police recently participated in a webinar on the introduction of robots into the federal government where he relayed his success using an ASR in a public park. According to the new client, the chief’s experience contributed to the decision to select Knightscope as an integral part of their security program.

Knightscope, Inc. (NASDAQ: KSCP), founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities targeting to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics, artificial intelligence and electric vehicles.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including multiple Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country.

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire. You can learn more about the crime fighting wins at

The company has achieved several milestones since its creation in 2013, including:

  • Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology (Made in the USA)
  • Operating for more than 1 million hours in the field and securing contracts across five time zones, from Hawaii to Rhode Island
  • Raising over $100 million since inception to build its technology from scratch and generating over $13 million in lifetime revenue, validating both the market opportunity and the technology

Growth Capital & Proposed Nasdaq Listing

With backing from more than 28,000 investors and four major corporations and over $100 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

On December 1, 2021, Knightscope announced the commencement of an offering of up to $40 million of its Class A common stock, with shares to be listed immediately following closing on the Nasdaq Global Market under the ticker symbol ‘KSCP’. The offering is for up to 4 million shares priced at $10 per share. Learn more at

Company Mission – Reimagining Public Safety

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting the 2+ million law enforcement and security professionals across the country.

Crime has an estimated negative economic impact in excess of $2 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one-to-one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings – and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $3 to $9 per hour, compared with approximately $85 for an armed off-duty law enforcement officer and $15 to $35 for an unarmed security guard.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has nine patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’. Learn more at

The ASRs and the related technologies were developed ground up by the company and are Made in the USA.

The Robot Roadshow

Knightscope has created the ultimate hybrid physical and virtual event, bringing its Autonomous Security Robot technologies to cities across the country for interactive and in-person demonstrations.

Each roadshow landing is hosted virtually by a Knightscope expert, and visitors can interact directly with each of the company’s ASRs and see the Knightscope Security Operations Center (KSOC) user interface in action. Learn more at

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.

Chief Financial Officer Mallorie Burke is a seasoned financial executive and strategic advisor for both private and publicly traded technology companies with a successful track record of mergers & acquisitions, corporate growth and exit strategies, including public listings.

General Counsel Peter Weinberg leverages 30 years of diverse corporate counsel experience, spanning from startups to well-established companies, private and public. He has significant experience training personnel at all levels in critical areas to improve corporate compliance and productivity.

Knightscope, Inc. (NASDAQ: KSCP), closed Tuesday's trading session at $3.3, off by 7.3034%, on 142,762 volume. The average volume for the last 3 months is 142,762 and the stock's 52-week low/high is $2.87/$27.50.

Recent News

Odyssey Group International Inc. (OTC: ODYY)

The QualityStocks Daily Newsletter would like to spotlight Odyssey Group International Inc. (OTC: ODYY).

  • Odyssey boasts a diverse development portfolio spanning both pharmaceutical candidates and medical devices
  • The company is evaluating PRV-002 for the treatment of concussion, a dramatically underserved indication that currently has no FDA-approved drug
  • With PRV-001, Odyssey aims to receive Orphan Drug designation, which could potentially accelerate its pathway to FDA approval and provide seven years of market exclusivity
  • CardioMap(R) is intended to provide early, non-invasive testing for heart disease and is being developed for a 510(k) regulatory pathway
  • Save-A-Life is a developmental anti-choking device that Odyssey expects to position as the “accepted” standard and leader in the treatment of choking incidents
  • The company’s sports advisory board is headlined by NFL Hall of Famers Kurt Warner & Brett Favre and two-time Olympic gold medalist Abby Wambach
  • Odyssey is guided by a senior management team with significant experience relating to refining acquired technologies, building commercial systems and forging strategic partnerships

Odyssey Group International (OTC: ODYY) is a medical technology company focused on developing lifesaving medical products that offer technological and clinical advantages over current standards of care.

Odyssey Group International Inc. (OTC: ODYY) is a medical technology company focused on developing lifesaving medical products that offer technological and clinical advantages over current standards of care.

The company’s portfolio of product technologies is diverse, featuring four unique medical products in development. Odyssey’s goal is to deliver superior products with enhanced clinical utility and market potential, thereby yielding a high rate of return for its shareholders and partners. It is guided by a senior management team with significant experience relating to refining technologies, building commercial systems and forging strategic partnerships.

Product Portfolio


Odyssey has two pharmaceutical products in development:

  • PRV-002 is a novel compound for the treatment of concussion, which currently has no FDA-approved drug. In pre-clinical studies, PRV-002 has been shown to significantly improve both neuroscore and memory score following injury in rats subjected to concussion models. Importantly, the first-in-class novel neurosteroid demonstrated no drug-related toxicity in these trials.
    • PRV-002 is currently being evaluated in a phase I clinical trial for the treatment of concussion, with phase II trials planned for launch in Fall 2022. Odyssey has also highlighted the potential of PRV-002 for additional indications such as Alzheimer’s disease, Parkinson’s disease, ALS and chromic traumatic encephalopathy (CTE).
  • PRV-001 is a novel compound intended to treat Niemann-Pick disease, a rare neurodegenerative-lysosomal storage disorder that affects an estimated 1 in 150,000 individuals in the U.S., demonstrating a 5x higher incidence in Middle Eastern populations.
    • Odyssey expects to receive Orphan Drug designation from the FDA for PRV-001, which would accelerate its pathway to FDA approval and provide seven years of market exclusivity.

Medical Devices

Odyssey is also developing two medical device candidates:

  • CardioMap® is intended to provide early, non-invasive testing for heart disease. The system offers a number of potential advantages over traditional EKGs, including requiring less training to operate, offering heightened sensitivity and coming in a small and portable form factor. CardioMap is being developed for a 510(k) regulatory pathway, which requires a study to demonstrate equivalence to legacy EKG offerings.
    • When approved, CardioMap is expected to be the only device in its class that has a predictive value, illustrating ‘grey’ areas where deterioration has begun but not yet led to pathology. Odyssey expects this feature to provide a powerful incentive for doctors to use the CardioMap device in end markets such as hospitals, doctors’ offices, rehabilitation centers and sports medicine practices.
  • Save-A-Life (SAL) is a patented, single-action, instantaneous, handheld, mechanical anti-choking device that creates a vacuum chamber in the mouth to dislodge throat obstructions in a matter of seconds, all without harm to the victim. The device is currently in development, with a proof of concept established.
    • Odyssey believes that, once FDA-approved, its anti-choking device will quickly become the “accepted” standard and leader in the treatment of choking incidents globally. Its low-cost manufacturing and convenient portable design give SAL a competitive edge over competing devices utilizing cumbersome masks.

Market Opportunities

Odyssey’s varied development pipeline positions it to address a number of sizable market opportunities with significant unmet medical need. Concussions alone currently account for medical costs of roughly $10-15 billion annually in the U.S., despite the lack of a currently approved FDA drug treatment. This need is particularly apparent in the military and sports industry, where the likelihood of athlete head-injury recurrence is estimated at 75%.

It is for this reason that, in March 2021, Odyssey announced the formation of a sports advisory board featuring well-known athletes supporting the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. Members of Odyssey’s sports advisory board include NFL Hall of Famers Kurt Warner & Brett Favre and two-time Olympic gold medalist Abby Wambach.

With its CardioMap platform, Odyssey is targeting the global cardiac monitoring market, which was valued at $28 billion in 2021 by Insight Partners and forecast to reach $43 billion by 2028.

Save-A-Life targets a similarly underserved market. Choking is the fourth-leading cause of death in children, and approximately 5,000 choking deaths occur each year in the U.S. While 95% of these deaths result from in-home incidents, current choking rescue devices fail to address in-home applications.

Management Team

Joseph Michael Redmond is the President, CEO and Chairman of Odyssey. He has over 30 years of commercial experience in medical device companies, previously serving as CEO of Parallax Health Sciences Inc., V.P. of Business Development for DxTech Inc. and V.P. of Sales and Marketing for Bioject Medical Technologies Inc. While at Bioject, Mr. Redmond helped raise over $15 million in capital, entered into several licensing and distribution deals with major biotech and pharmaceutical companies and grew the market cap of the company from under $10 million to over $400 million. He started his career at Abbott Labs and holds a B.A. from Denison University.

Christine M. Farrell is the company’s CFO and Secretary. Prior to joining Odyssey, Ms. Farrell was Vice President of Finance for Bioject Medical Technologies Inc. She also held accounting and financial management positions with Spar-Tek Industries, a manufacturer of high quality and cutting-edge technology for the plywood industry, and Action Machinery, a seller of new and used robotic machine tools and equipment. Ms. Farrell holds a B.A. in Accounting from the University of Washington and an M.B.A. from Willamette University.

Dr. Jacob W. Vanlandingham is Odyssey’s Head of Drug Development. Dr. Vanlandingham holds a Ph.D. in neuroscience with a molecular biology focus. He is a member of the Society for Neuroscience, American Society for Nutritional Sciences, National Neurotrauma Society, Faculty for Undergraduate Research in Neuroscience and the International Association of Medical Science Educators.

Odyssey Group International Inc. (OTC: ODYY), closed Tuesday's trading session at $0.238669, off by 4.6468%, on 66,300 volume. The average volume for the last 3 months is 66,300 and the stock's 52-week low/high is $0.11/$0.8293.

Recent News

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF)

The QualityStocks Daily Newsletter would like to spotlight Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF).

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has reported that, further to its news release dated May 16, 2022, the company has filed its annual financial statements, management’s discussion and analysis, and related certifications for the year ended Dec. 31, 2021, (collectively, the “annual filings”). Delic expects that the management cease trade order (the “MCTO”), which was issued on May 3, 2022, will be revoked in the coming days. While the MCTO remains in effect, the general investing public will continue to be able to trade Delic’s securities. However, for the duration of the MCTO, Delic’s chief executive officer and chief financial officer are precluded from trading in the securities of the company. To view the full press release, visit

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country.

Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. Its founders helped build the multi-billion-dollar cannabis industry and aim to do the same in psychedelics as it follows a similar path toward legalization. In its quest to advance the new psychedelic renaissance upon us, Delic has become the pioneer in its field, creating an ecosystem of opportunities by investing in cutting-edge ideas.

The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the ‎first psychedelic umbrella platform. It is currently a trusted source for those interested in ‎psychedelic culture, education, treatments, and more.

While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully legal opportunities like IP, new media, live events, ketamine clinics (with the ability to offer additional psychedelic treatments once legalized, and large-scale production and brings them under its big tent of resources and reach.

The Big Problems Delic Is Addressing

  • Fifty percent of Americans will meet the criteria for a mental health condition sometime in their lifetime. The FDA has approved psilocybin therapy as a breakthrough therapy for depression.
  • Every 40 seconds, someone in the world commits suicide. Ketamine has been shown to decrease thoughts of suicide significantly. In 2019, the FDA approved esketamine as a fast-acting antidepressant.
  • Traditional palliative care methods do not eradicate end-of-life (EOL) anxiety. LSD and psilocybin have been shown to reduce EOL anxiety for terminally ill patients. Eighty percent of terminally ill patients with psilocybin sessions experienced significant reductions in depression and anxiety.
  • Approximately 50 million people in the U.S. are addicted to some tobacco product. Research shows that psilocybin is helping people quit smoking.

The Delic Ecosystem

The Delic Ecosystem covers three main areas: media, health, and science. The media focus is educating and motivating the masses through a variety of digital platforms, like Delic’s Reality Sandwich digital magazine, a free public education platform providing psychedelic guides, news and ‎culture (1.4+ million page views in 2020 and 54k social media followers across all platforms); Meet Delic, the first-ever psychedelic wellness summit and the premier psychedelic wellness event based in Las Vegas (over 2,000 live attendees and 5,000+ email subscribers); and Delic Radio (over 43 episodes and 100k total streams). Delic has also been featured in numerous media outlets like Forbes, NBC News, The Joe Rogan Experience, Daily Beast, High Times, and The Dr. Drew Podcast.

The focus of Delic’s health operations is the most accessible psychedelic treatments that can help billions of people live happier lives. Delic does this through one of the largest ketamine clinic chains in the country, Ketamine Infusion Centers (KICs), a limited liability corporation formed under the laws of Arizona that runs three ketamine clinics located in Bakersfield, California, and Phoenix, Arizona. Its management team has over 15 years of experience in the clinic and medical space, scaling and operating over 20 clinics, with a plan to open 10 more clinics in the next 18 months. Together, these clinics have overseen 4,000+ treatments delivered to date.

The focus of Delic’s science operations is developing IP and advanced extraction and testing facilities that are the backbone of the legal market. Delic carries this out through Delic Labs, a licensed cannabis and psilocybin research laboratory based in Vancouver. It’s the only entity licensed by Health Canada to exclusively focus on research and development of psilocybin vaporization technology.

Founded by award-winning chemists, Delic Labs focuses on extraction optimization, analytical testing, and chemical process development to advance the cannabis and psilocybin industries. Health Canada gave it a Section 56 Exemption to work with psilocybin compounds, allowing the company to possess and research these products for development and quality control before they hit the market.

Latest Acquisition – Homestead Book Company

On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company. Homestead is a legacy counterculture distributor of psychedelic media. It’s also the creator of one of the first self-contained psilocybin mushroom grow kits.

The acquisition of Homestead is an exciting one, as it shows how Delic is increasing accessibility to this nascent industry within regulated jurisdictions. Homestead has sold tens of thousands of mushroom kits globally and was one of the earliest distributors for High Times and many other counterculture publications.

The Homestead acquisition allows Delic to increase its product offerings on its website, Reality Sandwich, which recently hit a record for average monthly traffic of over 200,000 unique visitors and over 2.6 million active readers in 2020.

Market Outlook

The psychedelic renaissance is here. Just in time to help address the global mental health crises, plant medicines have the potential to help billions of people live happier lives. Thanks to university-led and FDA-approved studies, North America is leading the way in advancing an industry as psychedelics are becoming accepted globally for therapeutic, medical, and recreational use. Here are some statistics:

  • 32 million people in the U.S. have used psychedelics at least once
  • 17% of all American adults between 21 and 64 have used psychedelics at least once
  • $500 billion is spent in the U.S. every year on prescription drugs
  • $238 billion is spent in the U.S. every year on mental health treatments and ancillary services
  • The anxiety disorder and depression treatment market is estimated at $16 billion
  • $187.8 billion was spent in 2013 on mental health and substance abuse disorders

Management Team

Delic Co-Founder and CCO Jackee Stang was an executive at High Times, a leading counterculture publication that became the voice for the cannabis industry. The monthly magazine had a circulation of over 500,000 copies per issue. Its website attracted 500,000 to five million users each month by 2014.

Likewise, company Co-Founder and CEO Matt Stang was a previous owner and operator of High Times, a position from which he played an instrumental in legalizing cannabis in multiple states and launched the Cannabis Cup in America. After interacting with the cannabis community for two decades, he helped found Delic in 2019 as one of the first psychedelic corporations. He shapes the company’s vision and path using his expertise in branding, marketing, business development, and product viability.

Delic’s VP of Business Development, John Coleman, Ph.D., is a former president of Anandia Labs, a biotech company focused on genetics and analytics. Having experience in both science and business, Dr. Coleman is well-equipped to lead Delic’s business development efforts as it strives to enter new vertical markets.

Zak Garcia is the company’s Chief Marketing Officer. He was the former CMO of Bulletproof Inc., maker of the well-known Bulletproof Coffee brand. Mr. Garcia is a marketing and leadership strategist who helped grow Bulletproof Coffee to over $250 million in revenue.

Delic Holdings Corp. (DELCF), closed Tuesday's trading session at $0.04606, off by 3.0316%, on 40,623 volume. The average volume for the last 3 months is 40,623 and the stock's 52-week low/high is $0.03308/$0.315.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.